The present disclosure is directed to lubricious medical devices that include an anti-microbial disposed on an outer surface of the medical device to enhance the anti-microbial properties of the medical device. More specifically, the present disclosure is directed to medical devices that include a sulfanilamide, substituted sulfanilamide and/or a sulfanilamide derivative disposed on the outer surface of the medical device.
Insertable medical devices such as catheters are used to treat and facilitate treatment for a wide variety of medical conditions. These insertable medical devices have a myriad of uses including opening bodily passageways, delivering drugs, and aiding surgeons in surgeries. For example, urinary catheters are used to treat urinary incontinence. Intermittent urinary catheters are often used for self-catherization in non-sterile environments. Because these devices are inserted into the body, sterility and maintaining sterility is advantageous in preventing infections.
In such devices, pathogens including bacteria and microbes may be present on the surface or, where applicable, the coating of the medical devices. These pathogens can contaminate the medical device, causing the sterility of the catheter to be compromised. This contamination may result in catheter users, many of whom may be at an increased risk for infection, developing an infection. Thus, there remains a need for medical devices which resist pathogenic contamination.
There are several aspects of the present subject matter which may be embodied separately or together in the devices and systems described and claimed below. These aspects may be employed alone or in combination with other aspects of the subject matter described herein, and the description of these aspects together is not intended to preclude the use of these aspects separately or the claiming of such aspects separately or in different combinations as set forth in the claims appended hereto.
In a first aspect, a medical device includes a surface, and at least one of a sulfanilamide or a diaminodiphenyl sulfone associated with the surface.
In another aspect, a method of making a medical device having antimicrobial properties is disclosed. The method includes reducing a diazonium sulfanilamide salt or a diazonium diaminodiphenyl sulfone salt in the presence of a reducing agent and a surface of the medical device whereby at least one of a sulfanilamide derivative or a diaminodiphenyl sulfone derivative attaches to the surface of the medical device.
The embodiments disclosed herein are for the purpose of providing a description of the present subject matter, and it is understood that the subject matter may be embodied in various other forms and combinations not shown in detail. Therefore, specific embodiments and features disclosed herein are not to be interpreted as limiting the subject matter as defined in the accompanying claims.
The medical device 100 comprises a surface 102. A sulfanilamide 104 (shown in
Turning to
The surface 102 of the medical device 100 may be a plastic or polymer surface. The reducing agent may include a metal, such as steel or aluminum. Alternatively, the reducing agent may be metallic powders including, but not limited to, steel, aluminum, iron, or zinc powder. In another alternative the surface of the device itself could be or could include the reducing agent. For example, the surface of the device could be a metal surface that acts as a reducing agent, or the surface could be a polymer that includes a metal reducing agent incorporated therein. In another alternative, organic reducing agents, such as but not limited to: acetyl phenyl hydrazine, tannic acid, benzoin, ascorbic acid (vitamin A), ascorbic acid 6-palmitate, alpha-tocopherol, gamma-tocopherol, 2,2,5,7,8-pentamethylchromanol, gallic acid [3,4,5-trihydroxybenzoic acid], pyrogallol [benzene-1,2,3-triol], hydroquinone and combinations thereof, may be used. The reducing agent may be formed in solution.
To form the diazonium sulfanilamide salt, the sulfanilamide 104 may undergo a diazotization reaction, as shown in the first reaction in the schematic of
The diazonium salt may be formed from a sulfanilamide such as:
wherein R1 comprises one of (i) hydrogen, (ii) acetyl groups, (iii) amido groups, (iv) guanidyl groups, (v) 5 or 6 membered heterocyclic aromatic groups, (vii) methoxy-substituted heteroaromatic compounds and (vi) alkyl-substituted heteroaromatic compounds.
The 5 or 6 membered heterocyclic aromatic groups contain one or more of nitrogen atom(s), oxygen atom(s) or sulfur atom(s).
For example, the sulfanilamide 104 may be one or more of the below or derivatives thereof:
Other known suitable sulfanilamides besides those listed above may also be used. One of ordinary skill could readily understand that the above listed sulfanilamide and substituted sulfanilamides (“sulfanilamides”) also represent corresponding derivatives of sulfanilamides. When attached to the medical device, the corresponding derivatives of the sulfanilamides have substantially the same structure as the above sulfanilamides except that the primary amine group of the sulfanilamides has been removed by reduction to facilitate attachment to the surface of the medical device. Reduction results in a covalently bound sulfanilamide attached to the surface of the medical device.
In an alternative to sulfanilamides, or in addition to, diaminodiphenyl sulfone (Dapsone) may be attached to the surface of a medical device using the same or similar mechanisms as disclosed herein. Diaminodiphenyl sulfone includes derivatives thereof, such as the diazonium forms of diaminodiphenyl sulfone. For example, diaminodiphenyl sulfone may be transformed into its mono or bis diazonium salt forms by the same or similar mechanisms as disclosed herein. The diazonium diaminodiphenyl sulfone salt may then be reduced in the presence of a medical device surface to attach diaminodiphenyl sulfone.
As shown in
Thus, upon grafting, the sulfanilamide or derivative thereof 104 attached to the surface of the medical device may be any of the above mentioned sulfanilamides. In particular, the sulfanilamide or derivative thereof may be:
wherein R1 is any of the above-mentioned components or functional groups.
In an embodiment, the grafting of the sulfanilamide 104 to the surface 102 of the medical device 100 may result in a monolayer—a thin layer of organic groups grafted to the surface 102. In alternative embodiments, a plurality of layers may be grafted onto the medical device, for example a bilayer may be formed on the surface, resulting in a thicker layer of organic groups grafted onto the surface.
The medical device 100 may be a catheter. As illustrated in
In alternative embodiments, the medical device may have a hydrophilic coating on a surface of the medical device. For example, a urinary catheter may have a hydrophilic coating disposed on the outer surface of the catheter. The sulfanilamide may be attached to the hydrophilic coating. For example, a lubricious hydrophilic polymer coating may be on the surface of the medical device. For example, the hydrophilic coating may be formed from polyvinylpyrrolidone or polyethylene oxide, which may optionally include agents and additives. In such an embodiment, the sulfanilamide may be grafted onto the hydrophilic coating. When the hydrophilic coating is contacted, wetted or hydrated with a hydration medium, it becomes lubricious. The lubricity eases introduction of the medical device into the body and aids in reducing pain and discomfort associated with such introduction. The hydrophilic coating can be a single layer or a multilayer hydrophilic coating. Multi-layered coating can include at least a base coat and a top layer. In other alternatives, coatings other than hydrophilic coatings may be on a surface of the medical device, wherein the sulfanilamide is attached to the coating.
The sulfanilamides described above are anti-bacterial, and anti-microbial. The sulfanilamides may be used to resist pathogens that infect the urinary tract and other areas of the body. For example, both sulfamethoxazole in combination with trimethoprim, and sulfadiazine may be useful in the treatment of urinary tract infections (UTIs). Sulfacetamide and its sodium salt are used in treatments for bacterial eye infections and also as a lotion used for the treatment of acne and dermatitis. Sulfaguanidine is a veterinary anti-bacterial used for intestinal infections. Thus, adding sulfanilamides, and their derivatives to a surface of the medical device and/or to the hydrophilic coating may help prevent contamination of the medical device and/or the coating by inhibiting the proliferation of pathogens such as bacteria, and microbes.
It will be understood that the embodiments described above are illustrative of some of the applications of the principles of the present subject matter. Numerous modifications may be made by those skilled in the art without departing from the spirit and scope of the claimed subject matter, including those combinations of features that are individually disclosed or claimed herein. For these reasons, the scope hereof is not limited to the above description but is as set forth in the following claims, and it is understood that claims may be directed to the features hereof, including as combinations of features that are individually disclosed or claimed herein.
The present application claims the benefit of and priority to U.S. Provisional Application No. 63/050,935, filed Jul. 13, 2020, which is hereby incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/041470 | 7/13/2021 | WO |
Number | Date | Country | |
---|---|---|---|
63050935 | Jul 2020 | US |